Campbell & Co Investment Adviser’s Celldex Therapeutics CLDX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,530	Closed	-$282K	–	1174
2025 Q1	$282K	Buy	+15,530	New	+$347K	0.02%	863
2024 Q2	–	Sell	-19,166	Closed	-$804K	–	1081
2024 Q1	$804K	Buy	+19,166	New	+$787K	0.07%	489
2022 Q3	–	Sell	-8,052	Closed	-$217K	–	732
2022 Q2	$217K	Sell	8,052 -640	-7%	-$18.6K	0.06%	579
2022 Q1	$296K	Buy	8,692 +1,092	+14%	+$34.9K	0.08%	479
2021 Q4	$294K	Sell	7,600 -3,500	-32%	-$153K	0.1%	368
2021 Q3	$599K	Buy	11,100 +3,100	+39%	+$145K	0.2%	163
2021 Q2	$268K	Buy	+8,000	New	+$220K	0.11%	354

Other funds holding CLDX

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Campbell & Co Investment Adviser's CLDX Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 15,530 shares — an estimated $282K sold.

Campbell & Co Investment Adviser first reported a position in CLDX in Q2 2021 and held it in 7 quarters. The position peaked at $804K in Q1 2024. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

Campbell & Co Investment Adviser reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 15,530 Celldex Therapeutics shares in Q2 2025, an estimated $282K.
Campbell & Co Investment Adviser first reported a position in Celldex Therapeutics in Q2 2021 and held it in 7 quarters.
Campbell & Co Investment Adviser's Celldex Therapeutics position peaked at $804K in Q1 2024.
180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.